Abbott Laboratories (ABT) decides to end its venture with Emergent BioSolutions (EBS) to develop...

|About: Abbott Laboratories (ABT)|By:, SA News Editor

Abbott Laboratories (ABT) decides to end its venture with Emergent BioSolutions (EBS) to develop and commercialize TRU-016, as the firm cites a shift in its portfolio priorities. Under the terms of the agreement, Emergent will retain worldwide rights for the development and commercialization of TRU-016 - a potential treatment of B-cell malignancies. Shares of ABT +0.7% premarket, EBS inactive.